We market well.
Your agency should fully understand your product and the science. Then, there’s the marketplace. Grasping all three dynamics is a specialized field. Ours.
Our philosophy implies there are no excuses for boring and dull. The medical industry deserves better.
Spread the word. Big or small. Any time, any place. Right now, today. Don’t wait, hesitate or ruminate. We can help all medical companies. We’d like to make your brand our next success story.
NOW IN PROGRESS
World’s 2nd most popular
search engine? YouTube.
People are naturally interested in other humans and information.
Attract, educate and engage with videos that tell your story—just keep it brief.
recent work right here
DAKAR (Reuters) - With more than twice as many Ebola outbreaks as any other country since the virus was discovered in 1976, Congolese are familiar with its destructive power, yet fear and suspicion of medical authorities are still hindering efforts at containment.... LONDON (Reuters) - AstraZeneca's immunotherapy drug Imfinzi has hit a second important goal by improving overall survival in lung cancer patients, boosting prospects for a medicine that has already got off to a promising commercial launch.... MUMBAI (Reuters) - Officials in a third Indian state were checking on Friday if two people had been infected with the brain-damaging Nipah virus that has killed 12 in southern Kerala, although the government described the outbreak as minor.... (Reuters) - A California jury on Thursday ordered Johnson & Johnson to pay $4 million in punitive damages to a woman who said she developed cancer after being exposed to asbestos in the company's baby powder, pushing the total damages award in the case to $25.7 million.... (Reuters) - U.S. regulators on Thursday approved BioMarin Pharmaceutical Inc's Palynziq for adults with phenylketonuria, a rare metabolic disorder, sending shares of the biotechnology company up 3 percent after hours.... WASHINGTON (Reuters) - The U.S. Environmental Protection Agency, under pressure from the chemical industry, has delayed release of a study detailing cancer risks from formaldehyde, according to internal communications seen by Reuters, potentially keeping important health information from the public.... ZURICH (Reuters) - Novartis said its Sandoz division received approval from the European Commission for its biosimilar Zessly (infliximab) in gastroenterological, rheumatological and dermatological diseases.... MELBOURNE (Reuters) - An Australian court dismissed an appeal by the nation's anti-trust watchdog in a case against Pfizer Inc in which the regulator alleged the company had used its market power to limit competition for its cholesterol-lowering drug Lipitor.... (Reuters) - Shares of Inogen Inc fell nearly 7 percent on Thursday after short seller Citron Research called the oxygen supply device maker the most expensive name in medical technology with no pipeline.... (Reuters Health) - People who eat at least two servings a week of oily fish like salmon, mackerel, herring and tuna should keep it up because U.S. doctors still say it's a good way to reduce the risk of heart attacks and strokes....